Increased Plasma Apolipoprotein C-III Concentration Independently Predicts Cardiovascular Mortality: The Hoorn Study
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Background: Hypertriglyceridemia is a cardiovascular risk factor. Apolipoprotein C-III (apoC-III) is an important determinant of the catabolic rate of triglyceride-rich lipoproteins. The aim of this study was to investigate the prognostic value of plasma apoC-III concentrations for cardiovascular mortality. Methods: We performed this prospective study in 2244 subjects (ages 49–77 years) who participated in the Hoorn Study. During a mean follow-up of 15 years, 504 individuals died: 231 of cardiovascular disease, 180 of cancer, and 93 of other causes. Cardiovascular disease risk factors and plasma apoC-III concentrations were measured at baseline. Results: The age- and sex-adjusted plasma apoC-III concentration was prospectively associated with cardiovascular mortality (P < 0.001). After adjustment for traditional risk factors, including fasting triglycerides, the hazard ratio (95% CI) for cardiovascular death between the highest and the lowest quartile of apoC-III was 1.85 (1.02–3.38). High concentrations of apoC-III did not appear to be associated with noncardiovascular mortality. Conclusions: In this general population cohort, a high apoC-III concentration in plasma, independently of fasting triglycerides and other traditional risk factors, predicts cardiovascular mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408 · cited 1×
“Increased plasma triglyceride concentrations are associated with increased coronary heart disease (CHD)7 risk ( 1 ).”
BackgroundSacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490
Ginsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R., & Brown, W. V. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112713 · Cited by 424 · cited 2×
“ApoC-III retards the clearance of triglyceriderich apoB-containing lipoproteins by inhibiting lipoprotein lipase (LPL), and as such plays a pivotal role in the catabolism of triglycerides ( 5 ).”
BackgroundKawakami, A., Aikawa, M., Alcaide, P., Luscinskas, F. W., Libby, P., & Sacks, F. M. (2006) · Circulation · doi:10.1161/circulationaha.106.622514 · Cited by 305
Kawakami, A., Aikawa, M., Libby, P., Alcaide, P., Luscinskas, F. W., & Sacks, F. M. (2006) · Circulation · doi:10.1161/circulationaha.105.591743 · Cited by 206
Onat, A., Hergenç, G., Sansoy, V., Fobker, M., Ceyhan, K., Toprak, S., & Assmann, G. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00025-x · Cited by 134 · cited 2×
“The cardiovascular risk associated with apoC-III concentrations has been previously investigated in several high-risk populations, e.g., patients with type 2 diabetes (10, 11), postmyocardial infarction (12), CHD (13), and the metabolic syndrome ( 14 ).”
BackgroundMarkers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity
Chan, D. C., Watts, G. F., Barrett, P. H., Mamo, J. C., & Redgrave, T. G. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.2.278 · Cited by 117 · cited 1×
“Obese men with insulin resistance were demonstrated to have higher concentrations of plasmaapoC-IIIandtriglyceride-richlipoproteinsand a lower estimated fractional catabolic rate of these particles ( 17 ).”
BackgroundOlin-Lewis, K., Krauss, R. M., La Belle, M., Blanche, P. J., Barrett, P. H. R., Wight, T. N., & Chait, A. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200322-jlr200 · Cited by 114 · cited 1×
“Furthermore, apoC-III enhances the binding of apoB-containing lipoproteins to vascular proteoglycans ( 9 ).”
Background
Cited by
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
Soppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 407
Tardif, J.-C., Karwatowska-Prokopczuk, E., Amour, E. S., Ballantyne, C. M., Shapiro, M. D., Moriarty, P. M., Baum, S. J., Hurh, E., Bartlett, V. J., Kingsbury, J., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab820 · Cited by 210
Schwartz, E. A., Koska, J., Mullin, M. P., Syoufi, I., Schwenke, D. C., & Reaven, P. D. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.028 · Cited by 173
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
Metadata
- Authors
- Scheffer, P. G., Teerlink, T., Dekker, J. M., Bos, G., Nijpels, G., Diamant, M., Kostense, P. J., Stehouwer, C. D. A., & Heine, R. J.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-08-01
- Volume
- 54
- Issue
- 8
- Pages
- 1325-1330
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2168420374
- Cited by
- 66
- References
- 13
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increased Plasma Apolipoprotein C-III Concentration Independently Predicts Cardiovascular Mortality: The Hoorn Study. https://app.cochat.ai/papers/10.1373/clinchem.2008.103234
- The paper
- Scheffer, P. G., Teerlink, T., Dekker, J. M., Bos, G., Nijpels, G., Diamant, M., Kostense, P. J., Stehouwer, C. D. A., & Heine, R. J. (2008). Increased Plasma Apolipoprotein C-III Concentration Independently Predicts Cardiovascular Mortality: The Hoorn Study. Clinical Chemistry. https://doi.org/10.1373/clinchem.2008.103234
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.